Your browser doesn't support javascript.
loading
Estimates of diagnosed dementia prevalence and incidence among diverse beneficiaries in traditional Medicare and Medicare Advantage.
Haye, Sidra; Thunell, Johanna; Joyce, Geoffrey; Ferido, Patricia; Tysinger, Bryan; Jacobson, Mireille; Zissimopoulos, Julie.
Afiliação
  • Haye S; USC Price School of Public Policy University of Southern California Los Angeles California USA.
  • Thunell J; Leonard D. Schaeffer Center for Health Policy & Economics University of Southern California Los Angeles California USA.
  • Joyce G; USC Price School of Public Policy University of Southern California Los Angeles California USA.
  • Ferido P; Leonard D. Schaeffer Center for Health Policy & Economics University of Southern California Los Angeles California USA.
  • Tysinger B; Leonard D. Schaeffer Center for Health Policy & Economics University of Southern California Los Angeles California USA.
  • Jacobson M; USC School of Pharmacy University of Southern California Los Angeles California USA.
  • Zissimopoulos J; Leonard D. Schaeffer Center for Health Policy & Economics University of Southern California Los Angeles California USA.
Alzheimers Dement (Amst) ; 15(3): e12472, 2023.
Article em En | MEDLINE | ID: mdl-37636488
Approximately half of Medicare beneficiaries are enrolled in Medicare Advantage (MA), a private plan alternative to traditional Medicare (TM). Yet little is known about diagnosed dementia rates among MA enrollees, limiting population estimates. All (100%) claims of Medicare beneficiaries using encounter data for MA and claims for TM for the years 2015 to 2018 were used to quantify diagnosed dementia prevalence and incidence rates in MA, compare rates to TM, and provide estimates for the entire Medicare population and for different racial/ethnic populations. In 2017, dementia incidence and prevalence among MA beneficiaries were 2.54% (95% confidence interval [CI]: 2.53 to 2.55) and 7.04% (95% CI: 7.03 to 7.06). Comparison to TM adjusted for sociodemographic and health differences among beneficiaries in MA and TM; the prevalence of diagnosed dementia among beneficiaries in MA was lower (7.1%; 95% CI: 7.12 to 7.13) than in TM (8.7%; 95% CI: 8.71 to 8.72). The diagnosed dementia incidence rate was also lower in MA (2.50%; 95% CI: 2.50 to 2.50) compared to TM (2.99%; 95% CI: 2.99 to 2.99). There were lower rates in MA compared to TM for men and women and White, Black, Hispanic, Asian, American Indian/Alaska Native persons. Diagnosed dementia prevalence and incidence for the entire Medicare population was 7.9% (95% CI: 7.91 to 7.93) and 2.8% (95% CI: 2.77 to 2.78). Lower diagnosed dementia rates in MA compared to TM may exacerbate racial/ethnic disparities in diagnosed dementia. Rates tracked over time will provide understanding of the impact on dementia diagnosis of 2020 MA risk adjustment for dementia.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Incidence_studies / Prevalence_studies / Risk_factors_studies Aspecto: Equity_inequality Idioma: En Revista: Alzheimers Dement (Amst) Ano de publicação: 2023 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Incidence_studies / Prevalence_studies / Risk_factors_studies Aspecto: Equity_inequality Idioma: En Revista: Alzheimers Dement (Amst) Ano de publicação: 2023 Tipo de documento: Article País de publicação: Estados Unidos